We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Link Technologies Secures Exclusive License for Ultra Sensitive Diagnostic Probes
News

Link Technologies Secures Exclusive License for Ultra Sensitive Diagnostic Probes

Link Technologies Secures Exclusive License for Ultra Sensitive Diagnostic Probes
News

Link Technologies Secures Exclusive License for Ultra Sensitive Diagnostic Probes

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Link Technologies Secures Exclusive License for Ultra Sensitive Diagnostic Probes"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The ISO 9001:2000 certified specialist oligonucleotide reagent manufacturer, Link Technologies Ltd, has announced an exclusive license deal with The University of Manchester Intellectual Property Limited (UMIP).

Under the terms of the license for the University’s “exciplex” technology, Link will manufacture and sell highly sensitive exciplex-based diagnostic reagents worldwide. Exciplex technology offers ultra-biospecificity and significantly increased detection sensitivity over conventional systems due to negligible background signal. This license marks the start of a forward collaboration between Link and the University to develop the existing technology.

Honorary Professor Ken Douglas and Dr Elena Bichenkova, a Senior Lecturer in Medicinal Chemistry at the University of Manchester, have developed new exciplex diagnostic probes based on labelling oligonucleotides with exciplex partners that form excited-state complexes in close spatial proximity. Application of these modified oligonucleotides in diagnostic systems has been shown to discriminate DNA mutations at the level of PCR products and plasmid DNA.

Professor Douglas commented: “This is a very exciting opportunity to bring together a University discovery base and this excellent company. The exciplex is a significant new area of science and we are pleased to have the expertise of Link Technologies to take this forward commercially for clinical benefit”.

Dr John Bremner, Business Development Director at Link Technologies, concurred: “We are delighted with this deal, which we firmly believe is the start of something truly exciting. Our ongoing collaboration with the University over the coming months will optimize the technology, allowing Link to launch a new range of innovative products targeted at diagnostic companies worldwide.”

Patents for this technology, covering all major market areas, are held by the University of Manchester and licensed to Link. Link Technologies has also secured the rights to any intellectual property arising from the collaboration with the University. No financial details of the agreement have been disclosed.
Advertisement